Relieves symptoms associated with oral inflammatory lesions and ulcerative lesions…. ANDA 205592, held by Cosette Pharms Nc. Triamcinolone Acetonide.
As of Nov 15, 2026, ANDA 205592 (Triamcinolone Acetonide), held by Cosette Pharms Nc, was first approved by FDA on Jan 12, 2017, with 0 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Triamcinolone Acetonide Dental Paste, USP 0.1% is indicated for adjunctive treatment and for the temporary relief of symptoms associated with oral inflammatory lesions and ulcerative lesions resulting from trauma.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jan 12, 2017 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Triamcinolone Acetonide0.1% · paste;dental | Triamcinolone Acetonide | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters
